BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22848244)

  • 1. A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER(+), PR(+), ER(+)PR(+) and HER2(-) expression in women.
    Zhang M; Guo LL; Cheng Z; Liu RY; Lu Y; Qian Q; Lei Z; Zhang HT
    Oncol Lett; 2011 Jul; 2(4):653-658. PubMed ID: 22848244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes.
    Vitiello GAF; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
    Breast Cancer Res Treat; 2019 Nov; 178(1):207-219. PubMed ID: 31364002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlations of polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility to gastric cancer].
    Zhou Y; Jin GF; Jiang GJ; Wang HM; Tan YF; Ding WL; Wang LN; Chen WS; Ke Q; Shen J; Xu YC; Shen HB
    Ai Zheng; 2007 Jun; 26(6):581-5. PubMed ID: 17562261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: a case-control study.
    Xu L; Zeng Z; Chen B; Wu X; Yu J; Xue L; Tian L; Wang Y; Chen M; Sung JJ; Hu P
    Oncol Lett; 2011 Mar; 2(2):371-377. PubMed ID: 22866090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population.
    Jin G; Wang L; Chen W; Hu Z; Zhou Y; Tan Y; Wang J; Hua Z; Ding W; Shen J; Zhang Z; Wang X; Xu Y; Shen H
    Int J Cancer; 2007 Mar; 120(6):1330-5. PubMed ID: 17187359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the TGFBR2 G-875A polymorphism and cancer risk: evidence from a meta-analysis.
    Huang YS; Zhong Y; Yu L; Wang L
    Asian Pac J Cancer Prev; 2014; 15(20):8705-8. PubMed ID: 25374194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk.
    Shi J; Kobayashi LC; Grundy A; Richardson H; SenGupta SK; Lohrisch CA; Spinelli JJ; Aronson KJ
    Breast Cancer Res Treat; 2017 Aug; 165(1):201-213. PubMed ID: 28589367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype.
    Parise C; Caggiano V
    J Breast Cancer; 2016 Jun; 19(2):112-21. PubMed ID: 27382386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS.
    Villa NM; Li N; Yeh MW; Hurvitz SA; Dawson NA; Leung AM
    Endocr Pract; 2015 Sep; 21(9):1040-5. PubMed ID: 26121443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of polymorphisms in transforming growth factor-β receptors with susceptibility to gastric cardia adenocarcinoma.
    Guo W; Dong Z; Guo Y; Chen Z; Yang Z; Kuang G
    Mol Biol Rep; 2012 Apr; 39(4):4301-9. PubMed ID: 21785915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of INF-γ functional single nucleotide polymorphism +874 T/A (rs2430561) in breast cancer risk.
    Al-Rashidi HE; Refaat S; Ahmed E; Hussein DT; Eltantawy FM; Hamed S
    Saudi J Biol Sci; 2021 Nov; 28(11):6289-6296. PubMed ID: 34759748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta 1 (TGFβ1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.
    Vitiello GAF; Guembarovski RL; Hirata BKB; Amarante MK; de Oliveira CEC; de Oliveira KB; Cebinelli GCM; Guembarovski AL; Campos CZ; Watanabe MAE
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):645-655. PubMed ID: 29362917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
    Xing P; Li J; Jin F
    Med Oncol; 2010 Sep; 27(3):926-31. PubMed ID: 19771534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
    Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
    Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.